J. Luna

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

N. Muñoz, C. Clavel, E. Myers, 2009, The Lancet.

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

J. C. Reina, E. Moreira, E. Lazcano-Ponce, 2017, Papillomavirus research.

Determinants of LSIL Regression in Women from a Colombian Cohort

N. Muñoz, M. Molano, H. Posso, 2010 .

Evaluation of the immune response to human papillomavirus types 16, 18, 31, 45 and 58 in a group of Colombian women vaccinated with the quadrivalent vaccine

P. Coursaget, A. Touzé, M. Molano, 2013 .

Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil™ in Adult Women

A. Saah, S. Vuocolo, D. Radley, 2013, PloS one.

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

N. Muñoz, X. Castellsagué, D. Ferris, 2011, British Journal of Cancer.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region☆

J. Cuzick, C. Wheeler, F. X. Bosch, 2016, Papillomavirus research.

Cervical cancer screening with naked‐eye visual inspection in Colombia

R. Cendales, R. Murillo, J. Luna, 2010, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.

C. Wheeler, F. X. Bosch, N. Muñoz, 2018, Obstetrics and gynecology.

Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease

Jack Cuzick, Jorma Paavonen, Cosette M. Wheeler, 2014, Cancer Epidemiology, Biomarkers & Prevention.